Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)

Trial Profile

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs HTD 1801 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors HighTide Biopharma
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 30 Apr 2019 to 3 Feb 2020.
    • 17 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 12 Oct 2019.
    • 12 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top